Niagen Bioscience
Logotype for Niagen Bioscience Inc

Niagen Bioscience (NAGE) investor relations material

Niagen Bioscience 18th Annual Southwest IDEAS Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Niagen Bioscience Inc
18th Annual Southwest IDEAS Conference summary19 Nov, 2026

NAD science and research

  • NAD supports cellular energy metabolism and damage repair; high levels were described as improving mitochondrial output and cellular resilience.

  • R&D focus includes 100+ patents, 500+ published studies, 52 peer-reviewed human clinical studies on nicotinamide riboside, and 300+ research collaborations.

  • A 200-participant, six-month Tru Niagen study found slowing or reversal of biological age on five of seven epigenetic clocks, according to the presentation.

Commercial products and growth opportunities

  • Tru Niagen is positioned as a leading single-ingredient supplement; ~60% of sales came through Amazon and Shopify, with ~$20M wholesale and ~$25M ingredient sales last year.

  • Injection and IV sales were estimated at $5M-$10M; distribution included 1,700 U.S. clinics and a recently launched at-home injection kit, with large telehealth discussions underway.

  • The U.S. NAD IV market was estimated at $500M; a Restore pilot across 200 stores made Niagen its flagship ingredient, with management optimistic about 2027 growth.

  • NanoCloud skincare was described as penetrating skin and elevating NAD in damaged skin; Estée Lauder discussions could lead to a Niagen product in the next few months.

Pharmaceutical pipeline and funding plans

  • NB4168, a proprietary prodrug, is being developed for rare diseases including ataxia-telangiectasia; two positive Phase II studies used Tru Niagen, while the program has shifted to NB4168.

  • Management estimated $30M-$40M of incremental spending over ~4 years to reach drug approval; licensing, co-financing, or spinoff arrangements may come sooner.

  • Management plans another 6-12 months of work before pursuing partnerships more aggressively; interested parties have approached, but current terms were viewed as insufficiently compelling.

  • Rare-disease approval may bring a transferable priority-review voucher; management cited recent voucher sales above $200M and potential orphan-drug pricing of $400,000-$1M per year.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Niagen Bioscience earnings date

Logotype for Niagen Bioscience Inc
Q4 20263 Mar, 2027
Niagen Bioscience
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Niagen Bioscience earnings date

Logotype for Niagen Bioscience Inc
Q4 20263 Mar, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

ChromaDex Corporation is a biosciences company that develops and markets ingredients and consumer products based on nicotinamide riboside and other proprietary compounds. Its product portfolio supports healthy aging and cellular health, distributed through e-commerce and retail. The company is headquartered in Los Angeles, California, and its shares are listed on the NASDAQ.